ExoFlo

Phase 3Biologic

DDirect Biologics, LLC

ExoFlo is one of 117 biologic programs targeting Anal fistula. It is currently in Phase 3.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anal FistulaActive, not recruiting

Ulcerative ColitisActive, not recruiting

COVID-19Active, not recruiting

Acute Respiratory Distress SyndromeActive, not recruiting

Anal FistulaPhase 1/Phase 2

Active, not recruiting

Ulcerative ColitisPhase 1

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Acute Respiratory Distress SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

ExoFlo

DDirect Biologics, LLC

Phase 3

3 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Acute Respiratory Distress Syndrome

NCT05354141

Clinical

Trials by Indication[1]

COVID-193 trials

Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS

Completed·DDirect Biologics, LLC·Phase 2·NCT04493242·102 enrolled

Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

No longer available·DDirect Biologics, LLC··NCT04657458

Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19

Withdrawn·DDirect Biologics, LLC·Phase 2·NCT05125562

Ulcerative Colitis1 trial

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

Terminated·DDirect Biologics, LLC·Phase 1·NCT05176366·4 enrolled

Anal fistula1 trial

Study of ExoFlo for the Treatment of Perianal Fistulas

Terminated·DDirect Biologics, LLC·Phase 1/2·NCT05836883·5 enrolled

Crohn's Disease1 trial

Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

Terminated·DDirect Biologics, LLC·Phase 1·NCT05130983·3 enrolled

Solid Organ Transplant1 trial

Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients

No longer available·DDirect Biologics, LLC··NCT05215288

1 more indication

Acute Respiratory Distress Syndrome1 trial

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Recruiting·DDirect Biologics, LLC·Phase 3·NCT05354141·970 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for ExoFlo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ExoFlo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ExoFlo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Direct Biologics, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: DDirect Biologics, LLC

ExoFlo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

COVID-193 trials

Ulcerative Colitis1 trial

Anal fistula1 trial

Crohn's Disease1 trial

Solid Organ Transplant1 trial

Acute Respiratory Distress Syndrome1 trial

References

Drug Info

Quick Facts

Related News